Maravai LifeSciences (MRVI) investor relations material

Executive summary

• Q2 2026 revenue reached $51.4 million, up 9% year-over-year, with TriLink growing 12% and Cygnus up 3%, both segments contributing to strong execution and margin expansion.

• Adjusted EBITDA improved by over $19.1 million year-over-year to $8.7 million, reflecting operational leverage, restructuring benefits, and positive margin trends.

• Net loss for Q2 was $(21.6) million, a significant improvement from $(69.8) million in Q2 2025; adjusted net loss was $(5.1) million.

• Innovation and commercial execution, including new GMP enzyme facility, ModTail™ adoption, and e-commerce growth, are driving customer acquisition and future margin expansion.

• Six-month revenue rose 24.4% year-over-year to $117.3 million, driven by TriLink's performance and CleanCap orders.

Financial highlights

• Q2 2026 revenue: $51.4 million (+8.5% YoY); TriLink: $34.7 million (+11.5% YoY); Cygnus: $16.8 million (+2.8% YoY).

• Adjusted gross margin expanded over 1,600 basis points to 58.9%; Q2 gross margin was 40.1–40.2%.

• Adjusted EBITDA was $8.7 million in Q2 2026, up from $(10.4) million in Q2 2025.

• Net loss per share improved to $(0.08) in Q2 2026 from $(0.27) in Q2 2025; adjusted EPS loss was $(0.02).

• Ended Q2 with $70.1 million in cash and $147.1 million in debt; net debt was $77.0 million.

Outlook and guidance

• 2026 revenue guidance maintained at $205–$215 million, representing 10–16% growth over 2025.

• Full-year adjusted EBITDA guidance raised to $33–$35 million, an improvement of $64–$66 million year-over-year.

• Gross margin expansion of over 1,400 basis points expected, driven by restructuring, cost discipline, and favorable mix.

• Guidance remains prudent due to variability in large program-driven orders and excludes impacts from future acquisitions.

• No further high-volume CleanCap orders for COVID-19 vaccine programs are expected for the remainder of 2026.